<?xml version="1.0" encoding="UTF-8"?>
<ack id="ceack10">
 <sec>
  <title>Acknowledgments</title>
  <p>Research reported in this manuscript was supported by the Division of AIDS, National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (NIH) under award numbers U01AI099959 and UM1AI068636, the US President's Emergency Plan for AIDS Relief (PEPFAR), and the Bill &amp; Melinda Gates Foundation. This research was also supported by the NIH under award numbers 2R01AI098472 (to MG for measurement of tenofovir hair concentrations) and K23MH114760 (to CAK). Gilead Sciences donated tenofovir disoproxil fumarateâ€“emtricitabine (Truvada) as a study drug. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH, PEPFAR, the Gates Foundation, or Gilead Sciences. The SEARCH study gratefully acknowledges the Ministries of Health of Kenya and Uganda, our research teams and administrative teams in San Francisco (CA, USA), Kenya, and Uganda, collaborators and advisory boards, and especially all communities and participants involved. We also thank Hideaki Okochi and Karen Kuncze of the Hair Analytical Laboratory at the University of California, San Francisco, CA, USA for their work on analysing tenofovir concentrations in hair samples provided by PrEP participants.</p>
 </sec>
</ack>
